Generation Bio's 15min chart sees MACD Death Cross, Bearish Marubozu formation.

As per the 15-minute chart of Generation Bio, there has been a noteworthy development in the MACD indicator, where a Death Cross has been triggered. Furthermore, the stock price has exhibited a bearish Marubozu pattern on August 28th, 2023, at 11:00. This suggests that the stock price has the potential to continue declining, with sellers maintaining control over the market. The bearish momentum is likely to persist, indicating a negative trend in the stock's performance.

The biopharma industry is experiencing a seismic shift in 2025, marked by significant layoffs, restructuring, and strategic realignments. While the headlines highlight job cuts and program shutdowns, this turbulence presents a golden opportunity for investors to identify undervalued companies with resilient pipelines poised for long-term growth.

The Layoff Landscape: A Double-Edged Sword
Over 30 biopharma firms have announced workforce reductions in 2025, with some cutting up to 90% of their staff. Merck's 8% global reduction (6,000 jobs), Moderna's 10% workforce trim, and CSL's 15% R&D cut reflect a sector under pressure. However, these moves are not all doom and gloom. Companies like Generation Bio and Bicycle Therapeutics are using these cuts to streamline operations, extend cash runways, and focus on high-impact programs. The key is to separate the companies that are bleeding out from those that are strategically pruning to regrow.

The Resilient Few: Pipelines That Outlive Layoffs
Let's spotlight firms that are maintaining or even strengthening their pipelines despite the chaos.

1. Generation Bio (NASDAQ: GBIO): A High-Risk, High-Reward Play
Layoff Impact: Cut 90% of its workforce in August 2025, including its entire R&D team.
Pipeline Resilience: Despite the drastic reduction, the company is pivoting to explore strategic alternatives (mergers, asset sales) while retaining its proprietary cell-targeted lipid nanoparticle (ctLNP) technology. Preclinical success in delivering siRNA to T cells in non-human primates suggests the platform has legs.
Financials: $141.4 million in cash as of Q2 2025, with a net cash position of $56 million. Analysts project a 75% upside to $10.67 per share.
Investment Thesis: This is a speculative bet. If a strategic partner or acquirer emerges, GBIO could unlock massive value. However, the lack of clinical trials and reliance on external validation make it a high-risk pick.

2. Bicycle Therapeutics (NASDAQ: BCYC): Cost-Cutting Without Compromise
Layoff Impact: 25% workforce reduction in 2025, with a cash runway now extended to 2028.
Pipeline Highlights:
Zelenectide pevedotin (Bicycle Drug Conjugate) is in Phase 1/2 trials for NECTIN4-amplified cancers (breast, lung, urothelial). Fast Track designation from the FDA adds regulatory tailwinds.
Bicycle Radioconjugate (BRC) program showed promising imaging data in MT1-MMP-targeted trials, with EphA2 imaging slated for 2026.
Financials: $721.5 million in cash as of June 2025, with R&D expenses of $59.1 million in Q1 2025.
Investment Thesis: The company is balancing cost discipline with pipeline momentum. Its focus on precision oncology and novel modalities (BRCs) positions it to capitalize on the $150 billion+ oncology market.

3. Absci (NASDAQ: ABSC): AI-Driven Efficiency
Layoff Impact: Undisclosed staff cuts in May 2025, but the company emphasized no impact on core AI, clinical, or R&D teams.
Pipeline Resilience: Absci's AI platform is accelerating drug discovery, with a cash runway into 2028. Recent collaborations with big pharma (e.g., Roche) validate its technology.
Financials: $200+ million in cash, with R&D expenses declining due to AI-driven efficiency.
Investment Thesis: Absci is a “buy-the-whisper” story. Its ability to reduce costs while advancing high-potential programs makes it a stealth winner in the AI-for-drugs space.

The Bigger Picture: Why These Companies Matter
The biopharma sector is consolidating, and the survivors will be those that prioritize quality over quantity in their pipelines. Companies like Dewpoint Therapeutics (70% staff cut but advancing DPTX3186 for gastric cancer) and Tune Therapeutics (25% reduction while maintaining hepatitis B focus) exemplify this strategy. These firms are not just surviving—they're repositioning for long-term growth by:
1. Extending cash runways through cost-cutting.
2. Focusing on high-impact programs with clear differentiation.
3. Leveraging strategic partnerships to de-risk development.

The Cramer-Style Verdict: Where to Play
Aggressive Investors: Generation Bio and Absci offer outsized potential but require a high tolerance for volatility.
Conservative Investors: Bicycle Therapeutics and Dewpoint Therapeutics provide a balance of pipeline strength and financial discipline.
Watch for Catalysts: FDA designations, partnership announcements, and trial readouts will be critical in 2025–2026.

The biopharma layoff wave is painful, but it's also a filter. The companies that endure—and thrive—are the ones with innovative science, lean operations, and a clear path to value creation. For investors willing to look beyond the headlines, these firms represent a rare chance to buy into tomorrow's leaders at today's prices.

References:
[1] https://www.ainvest.com/news/biopharma-layoff-wave-strategic-opportunities-industry-consolidation-2508/